Deuruxolitinib phosphate - Generic Drug Details
✉ Email this page to a colleague
What are the generic sources for deuruxolitinib phosphate and what is the scope of freedom to operate?
Deuruxolitinib phosphate
is the generic ingredient in one branded drug marketed by Sun Pharm Inds Inc and is included in one NDA. There are six patents protecting this compound. Additional information is available in the individual branded drug profile pages.One supplier is listed for this compound.
Summary for deuruxolitinib phosphate
| International Patents: | 64 |
| US Patents: | 6 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Clinical Trials: | 2 |
| Patent Applications: | 26 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for deuruxolitinib phosphate |
| What excipients (inactive ingredients) are in deuruxolitinib phosphate? | deuruxolitinib phosphate excipients list |
| DailyMed Link: | deuruxolitinib phosphate at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for deuruxolitinib phosphate
Generic Entry Date for deuruxolitinib phosphate*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for deuruxolitinib phosphate
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Concert Pharmaceuticals | Phase 1 |
Pharmacology for deuruxolitinib phosphate
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharm Inds Inc | LEQSELVI | deuruxolitinib phosphate | TABLET;ORAL | 217900-001 | Jul 25, 2024 | RX | Yes | Yes | 12,364,699 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharm Inds Inc | LEQSELVI | deuruxolitinib phosphate | TABLET;ORAL | 217900-001 | Jul 25, 2024 | RX | Yes | Yes | 10,561,659 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharm Inds Inc | LEQSELVI | deuruxolitinib phosphate | TABLET;ORAL | 217900-001 | Jul 25, 2024 | RX | Yes | Yes | 11,919,907 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Sun Pharm Inds Inc | LEQSELVI | deuruxolitinib phosphate | TABLET;ORAL | 217900-001 | Jul 25, 2024 | RX | Yes | Yes | 12,247,034 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | ||
| Sun Pharm Inds Inc | LEQSELVI | deuruxolitinib phosphate | TABLET;ORAL | 217900-001 | Jul 25, 2024 | RX | Yes | Yes | 12,076,323 | ⤷ Start Trial | ⤷ Start Trial | ||||
| Sun Pharm Inds Inc | LEQSELVI | deuruxolitinib phosphate | TABLET;ORAL | 217900-001 | Jul 25, 2024 | RX | Yes | Yes | 12,285,432 | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for deuruxolitinib phosphate
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Australia | 2017261286 | ⤷ Start Trial | |
| Australia | 2023201112 | ⤷ Start Trial | |
| Australia | 2025213576 | ⤷ Start Trial | |
| Brazil | 112018072339 | ⤷ Start Trial | |
| Canada | 3022519 | ⤷ Start Trial | |
| China | 109069493 | ⤷ Start Trial | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch